molbio®
INNOVATE • IMPACT • INSPIRE

Molbio Diagnostics Limited
(Formerly Molbio Diagnostics Private Limited)
Plot No. L-46, Phase II D, Verna Industrial Estate
Verna, Goa - 403722, India
+91 832 6724888 www.molbiodiagnostics.com

Date: September 5, 2026

To	**To**
BSE Limited ('BSE')	**National Stock Exchange of India Ltd**
Listing Department	**Exchange Plaza,**
Corporate Relationship Department	**Bandra-Kurla Complex,**
Phiroze Jeejeebhoy Towers,	**Bandra (E), Mumbai 400 051**
2nd Floor, Dalal Street,	**Symbol: MOLBIO**
Mumbai – 400 001	
BSE Script Code: 544866	

Subject: Outcome of Board Meeting held on Saturday, September 05, 2026.

Dear Sir(s)/Madam,

Pursuant to Regulation 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (the "SEBI Listing Regulations") along with relevant SEBI circulars, as applicable, we wish to inform that the Board of Directors of the Molbio Diagnostics Limited ("Company"), at its meeting held today i.e. Saturday, September 05, 2026, has, inter-alia, considered the following matters:

1. **Approval of Un-audited Financial Results (Standalone & Consolidated) for the quarter ended on June 30, 2026:-**

   Based on the recommendation of the Audit Committee of the Company, the Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 ("Financial Results"), which have been subjected to limited review by the Statutory Auditors of the Company in terms of Regulation 33 of the SEBI Listing Regulations has been approved.

   We are enclosing herewith the following as **Annexure I:**

   a. Un-audited Standalone Financial Results for the quarter ended on June 30, 2026 along with the Limited Review Report thereon;
   b. Un-audited Consolidated Financial Results for the quarter ended on June 30, 2026 along with the Limited Review Report thereon

2. **Authorization to the Key Managerial Personnel ("KMPs") of the Company to determine the materiality of an event or Information:-**

   Pursuant to Regulation 30(5) of SEBI Listing Regulations, and the Company's Policy on Determination of Materiality of information /events, the Board of Directors of the Company have authorized the Key Managerial Personnel ("KMPs") of the Company to determine the materiality of an event or Information and to make appropriate disclosure on timely basis to the stock exchanges under Regulation 30 of SEBI Listing Regulations. Accordingly, the details of the KMP's authorization to determine materiality of events or information is as follows:

Name	Designation	Contact Details	Email Id
Sriram Natarajan	Director & Chief Executive Officer(CEO)	08326724888	investors@molbiodiagnostics.com Address: Plot No.L-46, Phase II-D Verna Industrial Area,Verna, South Goa, Salcete, Goa, India, 403722
Chandrasekhar Nair	Director- Chief Technical Officer (CTO)		
Manan Bimal Khokhani	Chief Financial Officer(CFO)		
Darshan Karekar	Company Secretary & Compliance Officer		

The meeting commenced at 11:47 A.M. and ended at 04.00 P.M.

This intimation is also available on the Company's website at https://www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI Listing Regulations.

You are requested to take the above information on record.

Thanking You.

Yours Faithfully,

For Molbio Diagnostics Limited

DARSHAN RAGHUNATH KAREKAR
Digitally signed by DARSHAN RAGHUNATH KAREKAR
Date: 2026.09.05 18:39:00 +05'30'

Darshan Raghunath Karekar
Company Secretary & Compliance Officer
M. No: F13569
Place: Verna-Goa

12th Floor
"UB City" Canberra Block
No. 24, Vittal Mallya Road
Bengaluru - 560 001, India
Tel : +91 80 6648 9000

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Molbio Diagnostics Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Molbio Diagnostics Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The comparative financial information of the Company for the quarter ended June 30, 2025 and quarter ended March 31, 2026 included in the accompanying unaudited standalone financial results, were not reviewed or audited by us and have been compiled by the Management and approved by the Board of Directors of the Company.

For S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants
ICAI Firm registration number: 101049W/E300004

Sandeep Karnani

per Sandeep Karnani
Partner
Membership No.: 061207

S.R. Batliboi & Associates LLP
Bengaluru

UDIN: 26061207NGNRXF6543

Place: Bengaluru
Date: September 05, 2026

Molbio Diagnostics Limited
(formerly Molbio Diagnostics Private Limited)
CIN: U33125GA2000PLC002909
Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722
Phone no: +91 832 6724888 ; Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com

Statement of unaudited standalone financial results for the quarter ended June 30, 2026

(Amount in ₹ Million, except as stated otherwise)

	Particulars	Quarter ended			Year Ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		Unaudited	(Refer note 10)	(Refer note 10)	Audited
I	**Income**				
	Revenue from operations	3,993.78	4,387.10	953.20	13,133.98
	Other income	13.68	27.43	14.82	77.15
	Total income	**4,007.46**	**4,414.53**	**968.02**	**13,211.13**
II	**Expenses**				
	Cost of raw material and components consumed	1,267.24	1,628.20	846.45	4,849.90
	Purchase of traded goods	60.92	11.96	6.05	49.30
	Decrease / (increase) in inventories of finished goods, work-in-progress and stock-in-trade	114.35	42.07	(455.27)	156.26
	Employee benefit expenses	247.56	248.46	162.38	812.26
	Depreciation and amortisation expenses	84.18	98.46	74.14	357.33
	Finance costs	86.62	92.75	18.88	231.54
	Other expenses	1,387.35	1,386.02	490.00	4,747.68
	Total expenses	**3,248.22**	**3,507.92**	**1,142.63**	**11,204.27**
III	**Profit / (loss) before tax and exceptional item (I - II)**	**759.24**	**906.61**	**(174.61)**	**2,006.86**
IV	Exceptional item (Refer note 5)	-	-	-	31.34
V	**Profit / (loss) before tax (III - IV)**	**759.24**	**906.61**	**(174.61)**	**1,975.52**
VI	**Tax expenses**				
	(a) Current tax	221.99	286.49	-	599.74
	(b) Deferred tax (credit) / charge	(29.02)	(36.82)	(40.56)	(70.51)
	Total tax expenses	**192.97**	**249.67**	**(40.56)**	**529.23**
VII	**Profit / (loss) for the period / year (V - VI)**	**566.27**	**656.94**	**(134.05)**	**1,446.29**
VIII	**Other comprehensive income / (loss)**				
	Other comprehensive income / (loss) not to be reclassified to profit or loss:				
	(i) Re-measurement gains / (losses) on defined benefit plan	(0.84)	0.95	(2.31)	0.11
	Income tax effect on above	0.21	(0.24)	0.58	(0.03)
	Total other comprehensive income / (loss) for the period / year (net of tax)	**(0.63)**	**0.71**	**(1.73)**	**0.08**
IX	**Total comprehensive income / (loss) (net of tax) (VII + VIII)**	**565.64**	**657.65**	**(135.78)**	**1,446.37**
X	**Paid-up equity share capital (face value ₹ 1 each fully paid)**	**112.76**	**112.76**	**22.56**	**112.76**
XI	**Other Equity**				**11,234.33**
XII	**Earnings per equity share (EPS) (face value - ₹ 1 each) (not annualised for interim periods) (Refer note 9)**				
	Basic EPS (₹)	5.02	5.83	(1.19)	12.83
	Diluted EPS (₹)	5.02	5.83	(1.19)	12.83

See accompanying notes to the unaudited standalone financial results

S.R. Batliboi & Associates LLP Bengaluru

Molbio Diagnostics Limited GOA

Molbio Diagnostics Limited
(formerly Molbio Diagnostics Private Limited)
CIN: U33125GA2000PLC002909
Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722
Phone no: +91 832 6724888 ; Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com

Statement of unaudited standalone financial results for the quarter ended June 30, 2026

Notes

1 The Statement of unaudited standalone financial results for the quarter ended June 30, 2026 of Molbio Diagnostics Limited ("the Company") have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on September 05, 2026. The statutory auditors have conducted a limited review of the above unaudited standalone financial results for the quarter ended June 30, 2026.

2 The Statement of unaudited standalone financial results for the quarter ended June 30, 2026 of the Company has been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3 Subsequent to the quarter ended June 30, 2026, the Company has completed its Initial Public Offer (IPO) of 11,646,246 equity shares (includes employee reservation portion of 20,519 equity shares) of face value of ₹ 1 each at an issue price of ₹ 807 per equity share per share to investors and at an issue price of ₹ 731 per equity share to employees. The issue consisted of a fresh issue of 2,480,246 equity shares aggregating to ₹ 2,000.00 Million and an offer for sale of 9,166,000 equity shares by selling shareholders aggregating to ₹ 7,396.96 Million. The Company's equity shares were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on August 17, 2026.

Accordingly, the statement of unaudited financial results for the quarter ended June 30, 2026 have been drawn up for the first time in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

4 The shareholders of the Company through a special resolution approved the 'Employee Stock Option Plan 2025 ("ESOP 2025"/ "Plan") for creation of ESOP pool of 2,819,000 options having face value of ₹ 1/- each. However, no stock options have been granted as at June 30, 2026.

5 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws, collectively referred to as the 'New Labour Codes'. The Company had assessed and disclosed the incremental impact of these changes, which has resulted in increase in gratuity liability by ₹ 23.15 Million and increase in leave liability (compensated absences) by ₹ 8.19 Million. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company had presented this incremental amount as exceptional item for the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules there to.

6 A survey under Section 133A of the Income-tax Act, 1961 ("IT Act"), was carried out at the premises of the Company, by the Income Tax authorities during the year ended March, 2024 followed by search closure visits on various dates to check the compliance with the provisions of the IT Act. The income tax department has subsequently sought certain information/ clarifications, which have been submitted by the Company.

The department has raised tax demands aggregating to ₹ 208.71 Million plus interest and penalty, as applicable, vide assessment / reassessment order for the AY 2020-21 to 2024-25. In response to the same, the Company has made appeal to the Commissioner Income Tax (Appeals) along with rectification applications.

Management believes that the Company has complied with all the applicable provisions of the IT Act with respect to its operations. The Company has paid an amount of ₹ 78.95 Million as at June 30, 2026 under protest in connection with the survey. The management of the Company is confident of favourable outcome and accordingly no adjustments have been made in the unaudited standalone financial results for the quarter ended June 30, 2026 in this regard.

7 a. During the year ended March 31, 2025, the Company, OptraSCAN, Inc. ("OptraSCAN"), its promoters and other existing shareholders entered into a Stock Purchase Agreement. Pursuant to the agreement, the Company subscribed to 2,918,827 Series B preferred shares (no par value), representing a 19.68% equity interest in OptraSCAN, for a consideration of ₹ 415.52 Million (USD 4.90 Million). Accordingly, OptraSCAN became an associate of the Company. Further, during the year ended March 31, 2026, the Company subscribed to an additional 14,951,540 Series B preferred shares (no par value) of OptraSCAN for a consideration of ₹2,220.91 Million (USD 25.10 Million). Pursuant to this acquisition, effective November 01, 2025, the Company's shareholding increased to 60%, resulting in OptraSCAN becoming a subsidiary of the Company.

b. As at March 31, 2026, the Company held a stake of 65.47% in Prognosys Medical Systems Private Limited ("PMS"). During the quarter ended June 30, 2026, the Company acquired an additional stake of 4.53% in PMS from the existing shareholders. Consequently, the Company's cumulative shareholding in PMS increased from 65.47% to 70.00%.

8 The operating segment of the Company is identified to be "manufacturing of diagnostic devices, chips, reagents, etc" and the Chief Operating Decision Maker reviews business performance at an overall company level constituting a single segment. Therefore, the disclosure as per Ind AS 108 "Operating segments" and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended is not applicable to the Company.

9 During the quarter ended September 30, 2025, the Company has allotted the bonus shares aggregating to 90,207,800 equity shares in accordance with Section 63 of the Act in the ratio of 4:1 i.e., 4 fully paid-up equity shares for every 1 equity share of face value of ₹ 1 each. In accordance with the provision of Ind AS 33, Basic and Diluted EPS for the quarter ended June 30, 2025 have been adjusted retrospectively and presented, accordingly.

10 The figures for the quarter ended March 31, 2026 represent the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the unaudited year-to-date figures for the nine months period ended December 31, 2025, as compiled by management and which was not subjected to audit or review by the statutory auditors. Further, the figures for the quarter ended June 30, 2025 have also been complied by management. Neither the figures for the quarter ended March 31, 2026 nor those for the quarter ended June 30, 2025 have been subjected to audit or review by the statutory auditors.

S. R. Batliboi & Associates LLP
Bengaluru

Place : Goa
Date : September 05, 2026

MOLBIO DIAGNOSTICS LIMITED
GOA

For Molbio Diagnostics Limited

Sriram Natarajan
CEO & Director
DIN: 00013843

S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants

12th Floor
"UB City" Canberra Block
No. 24, Vittal Mallya Road
Bengaluru - 560 001, India
Tel : +91 80 6648 9000

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Molbio Diagnostics Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Molbio Diagnostics Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S. No.	Name of the Entity	Relationship
1	Molbio Diagnostics Limited	Holding Company
2	Bigtec Private Limited	Subsidiary
3	OptraScan INC	Subsidiary
4	OptraScan India Private Limited	Subsidiary
5	Prognosys Medical Systems Private Limited	Subsidiary
6	Prognosys Healthcare (India) Private Limited	Subsidiary
7	Chayagraphics (India) Private Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant

S.R. Batliboi & Associates LLP Bengaluru rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:

   - Four subsidiaries, whose unaudited interim financial results include total revenues of ₹ 125.20 Million, total net loss after tax of ₹ 130.27 Million, total comprehensive loss of ₹ 131.93 Million, for the quarter ended June 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors.

   - One associate, whose unaudited interim financial results include Group's share of net loss of ₹ 0.01 Million and Group's share of total comprehensive loss of ₹ 0.01 Million for the quarter ended June 30, 2026, as considered in the Statement whose interim financial results, other financial information has been reviewed by their respective independent auditors.

   The independent auditor's reports on unaudited interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement in respect of matters stated in paragraph 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results.

7. The comparative consolidated financial information of the Group for the quarter ended June 30, 2025 and quarter ended March 31, 2026 included in the accompanying unaudited consolidated financial results, were not reviewed or audited by us and have been compiled by the Management and approved by the Board of Directors of the Holding Company.

For S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI Firm registration number: 101049W/E300004

per Sandeep Karnani
Partner
Membership No.: 061207

S.R. Batliboi & Associates LLP Bengaluru

UDIN: 26061207HXWBOB3802

Place: Bengaluru
Date: September 05, 2026

Molbio Diagnostics Limited
(formerly Molbio Diagnostics Private Limited)
CIN: U33125GA2000PLC002909
Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722
Phone no: +91 832 6724888 ; Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com
Statement of unaudited consolidated financial results for the quarter ended June 30, 2026

(Amount in ₹ Million, except as stated otherwise)

	Particulars	Quarter ended			Year Ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		Unaudited	(Refer note 11)	(Refer note 11)	Audited
I	**Income**				
	Revenue from operations	4,083.76	5,606.22	997.08	14,456.87
	Other income	31.00	47.87	7.60	94.83
	Total income	**4,114.76**	**5,654.09**	**1,004.68**	**14,551.70**
II	**Expenses**				
	Cost of raw material and components consumed	1,314.70	2,419.79	779.41	5,699.23
	Purchase of traded goods	62.63	9.23	6.70	49.66
	Decrease / (increase) in inventories of finished goods, work-in-progress and stock-in-trade	119.50	(75.12)	(434.37)	12.86
	Employee benefit expenses	459.20	459.20	281.78	1,452.27
	Depreciation and amortisation expenses	170.75	196.02	123.19	636.40
	Finance costs	106.99	120.78	36.13	334.66
	Other expenses	1,121.89	1,205.86	516.13	4,028.42
	Total expenses	**3,355.66**	**4,335.76**	**1,308.97**	**12,213.50**
III	**Profit / (loss) before tax, share of loss of associates and exceptional items (I - II)**	**759.10**	**1,318.33**	**(304.29)**	**2,338.20**
IV	Share of loss of associates, net of tax	(0.01)	(0.01)	(8.49)	(21.98)
V	**Profit / (loss) before tax and exceptional items (III + IV)**	**759.09**	**1,318.32**	**(312.78)**	**2,316.22**
VI	Exceptional items (net) (Refer note 5 and 7)	-	-	-	4.85
VII	**Profit / (loss) before tax (V - VI)**	**759.09**	**1,318.32**	**(312.78)**	**2,311.37**
VIII	**Tax expenses**				
	(a) Current tax	285.46	347.28	-	732.93
	(b) Deferred tax (credit) / charge	(53.81)	12.75	(73.34)	(62.96)
	Total tax expenses	**231.65**	**360.03**	**(73.34)**	**669.97**
IX	**Profit / (loss) for the period / year (VII - VIII)**	**527.44**	**958.29**	**(239.44)**	**1,641.40**
X	**Other comprehensive income / (loss)**				
	(A) Other comprehensive income / (loss) not to be reclassified to profit or loss:				
	(i) Re-measurement gains / (losses) on defined benefit plan	(3.20)	2.14	(3.53)	1.45
	Income tax effect on above	0.91	(0.50)	0.89	(0.82)
	(B) Other comprehensive income / (loss) to be reclassified to profit or loss:				
	(i) Exchange gain / (loss) on translating the financial statements of foreign operations	(1.34)	121.89	-	153.64
	Income tax effect on above	-	-	-	-
	(ii) Share of other comprehensive gain / (loss) of an associate	-	-	-	3.23
	Income tax effect on above	-	-	-	(0.03)
	Total other comprehensive income / (loss) for the period / year (net of tax)	**(3.63)**	**123.53**	**(2.64)**	**157.47**
XI	**Total comprehensive income / (loss) for the period / year (net of tax) (IX + X)**	**523.81**	**1,081.82**	**(242.08)**	**1,798.87**
XII	**Profit / (loss) for the period / year attributable to:**				
	(a) Owners of the Parent Company	587.47	908.27	(237.14)	1,665.94
	(b) Non-controlling interest	(60.03)	50.02	(2.30)	(24.54)
XIII	**Other comprehensive income / (loss) for the period / year attributable to:**				
	(a) Owners of the Parent Company	(2.92)	75.59	(2.64)	96.51
	(b) Non-controlling interest	(0.71)	47.94	-	60.96
XIV	**Total comprehensive income / (loss) for the period / year attributable to:**				
	(a) Owners of the Parent Company	584.55	983.86	(239.78)	1,762.45
	(b) Non-controlling interest	(60.74)	97.96	(2.30)	36.42
XV	**Paid-up equity share capital (face value ₹ 1/- each fully paid)**	112.76	112.76	22.56	112.76
XVI	**Other equity**				11,580.60
XVII	**Earnings per equity share (EPS) (face value - ₹ 1 each) (not annualised for interim periods) (Refer note 9)**				
	Basic EPS, computed on the basis of profit / (loss) for the period / year attributable to owners of the Parent Company (₹)	5.21	8.05	(2.10)	14.77
	Diluted EPS, computed on the basis of profit / (loss) for the period / year attributable to owners of the Parent Company (₹)	5.21	8.05	(2.10)	14.77

See accompanying notes to the unaudited consolidated financial results

S. R. Batliboi & Associates LLP
Bengaluru

MOLBIO DIAGNOSTICS LIMITED
GOA

Molbio Diagnostics Limited
(formerly Molbio Diagnostics Private Limited)
CIN: U33125GA2000PLC002909
Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722
Phone no: +91 832 6724888 ; Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com

Statement of unaudited consolidated financial results for the quarter ended June 30, 2026

Notes

1 The Statement of unaudited consolidated financial results for the quarter ended June 30, 2026 of Molbio Diagnostics Limited ("the Holding Company" or "the Company"), its subsidiaries and associates (together hereinafter referred to as the "Group") have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company in their meeting held on September 05, 2026. The statutory auditors have conducted a limited review of the above unaudited consolidated financial results for the quarter ended June 30, 2026.

2 The Statement of unaudited consolidated financial results for the quarter ended June 30, 2026 has been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

3 Subsequent to the quarter ended June 30, 2026, the Holding Company has completed its Initial Public Offer (IPO) of 11,646,246 equity shares (includes employee reservation portion of 20,519 equity shares) of face value of ₹ 1 each at an issue price of ₹ 807 per equity share per share to investors and at an issue price of ₹ 731 per equity share to employees. The issue consisted of a fresh issue of 2,480,246 equity shares aggregating to ₹ 2,000.00 Million and an offer for sale of 9,166,000 equity shares by selling shareholders aggregating to ₹ 7,396.96 Million. The Holding Company's equity shares were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on August 17, 2026.

Accordingly, the statement of unaudited consolidated financial results for the quarter ended June 30, 2026 have been drawn up for the first time in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

4 The shareholders of the Holding Company through a special resolution approved the 'Employee Stock Option Plan 2025 ("ESOP 2025"/ "Plan") for creation of ESOP pool of 2,819,000 options having face value of ₹ 1/ each. However, no stock options have been granted as at June 30, 2026.

5 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws, collectively referred to as the 'New Labour Codes'. The Group had assessed and disclosed the incremental impact of these changes, which has resulted in increase in gratuity liability by ₹ 35.08 Million and increase in leave liability (compensated absences) by ₹ 8.19 Million. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group had presented this incremental amount as exceptional item for the year ended March 31, 2026. The Group continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules there to.

6 A survey under Section 133A of the Income-tax Act, 1961 ("IT Act"), was carried out at the premises of the Holding Company and Bigtec Private Limited, a subsidiary, by the Income Tax authorities during the year ended March, 2024 followed by search closure visits on various dates to check the compliance with the provisions of the IT Act. The income tax department has subsequently sought certain information/ clarifications, which have been submitted by the Holding Company.

The department has raised tax demands aggregating to ₹ 208.71 Million plus interest and penalty, as applicable on the Holding Company, vide assessment / reassessment order for the AY 2020-21 to 2024-25. In response to the same, the Holding Company has made appeal to the Commissioner Income Tax (Appeals) along with rectification applications.

Management believes that the Holding Company has complied with all the applicable provisions of the IT Act with respect to its operations. The Holding Company has paid an amount of ₹ 78.95 Million as at June 30, 2026 in connection with the survey. The management of the Holding Company is confident of favourable outcome and accordingly no adjustments have been made in the unaudited consolidated financial results for the quarter ended June 30, 2026 in this regard.

7 a. During the year ended March 31, 2025, the Holding Company, OptraSCAN, Inc. ("OptraSCAN"), its promoters and other existing shareholders entered into a Stock Purchase Agreement. Pursuant to the agreement, the Holding Company subscribed to 2,918,827 Series B preferred shares (no par value), representing a 19.68% equity interest in OptraSCAN, for a consideration of ₹ 415.52 Million (USD 4.90 Million). Accordingly, OptraSCAN became an associate of the Holding Company. Further, during the year ended March 31, 2026, the Holding Company subscribed to an additional 14,951,540 Series B preferred shares (no par value) of OptraSCAN for a consideration of ₹2,220.91 Million (USD 25.10 Million). Pursuant to this acquisition, effective November 01, 2025, the Holding Company's shareholding increased to 60%, resulting in OptraSCAN becoming a subsidiary of the Holding Company. Pursuant to this acquisition, the Group had derecognised its investment in associate as it now holds 60% interest and have gained control as a subsidiary. Accordingly share of loss amounting to ₹ 38.42 million has been recognised as gain on remeasurement of previously held interest in associate and has been disclsoed as an exceptional item for the year ended March 31, 2026.

b. As at March 31, 2026, the Holding Company held a stake of 65.47% in Prognosys Medical Systems Private Limited ("PMS"). During the quarter ended June 30, 2026, the Holding Company acquired an additional stake of 4.53% in PMS from the existing shareholders. Consequently, the Holding Company's cumulative shareholding in PMS increased from 65.47% to 70.00%.

8 The operating segment of the Group is identified to be "manufacturing of Diagnostic Devices, chips, reagents, etc" and the Chief Operating Decision Maker reviews business performance at an overall company level constituting a single segment. Therefore, the disclosure as per Ind AS 108 "Operating segments" and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended is not applicable to the Group.

9 During the quarter ended September 30, 2025, the Holding Company has allotted the bonus shares aggregating to 90,207,800 equity shares in accordance with Section 63 of the Act in the ratio of 4:1 i.e., 4 fully paid-up equity shares for every 1 equity share of face value of ₹ 1 each. In accordance with the provision of Ind AS 33, Basic and Diluted EPS for the quarter ended June 30, 2025 have been adjusted retrospectively and presented, accordingly.

10 Unaudited consolidated financial results for the quarter ended June 30, 2026, includes the unaudited financial results of subsidiaries Bigtec Private Limited, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited, OptraSCAN Inc. w.e.f. November 01, 2025 (associate till October 31, 2025), OptraScan India Private Limited w.e.f. November 01, 2025 (associate till October 31, 2025) and associate Chayagraphics (India) Private Limited.

11 The figures for the quarter ended March 31, 2026 represent the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the unaudited year-to-date figures for the nine months period ended December 31, 2025, as compiled by management and which was not subjected to audit or review by the statutory auditors. Further, the figures for the quarter ended June 30, 2025 have also been complied by management. Neither the figures for the quarter ended March 31, 2026 nor those for the quarter ended June 30, 2025 have been subjected to audit or review by the statutory auditors.

S.R. Batliboi & Associates LLP
Bengaluru

MOLBIO DIAGNOSTICS LIMITED
GOA

For Molbio Diagnostics Limited

Place : Goa
Date : September 05, 2026

Sriram Natarajan
CEO & Director
DIN: 00013843